TuHURA Biosciences, Inc./NV
Business
TuHURA Biosciences is a phase 3 immuno-oncology company developing novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's lead product, IFx-2.0, is an innate immune agonist designed to overcome checkpoint inhibitor resistance and is in a Phase 3 trial for advanced Merkel cell carcinoma. TuHURA also acquired TBS-2025, a VISTA-inhibiting monoclonal antibody, and is developing Delta Opioid Receptor-targeted bi-functional antibody-drug conjugates to modulate myeloid-derived suppressor cells in the tumor microenvironment.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-06-30 | FY 2023 2023-12-31 | FY 2023 2023-06-30 |
|---|---|---|---|---|---|---|
| Research and development expenses | 21 | 13 | 3 | 9 | 9 | |
| Acquisition-related costs (note 5) | 4 | 440,340 | — | — | — | |
| General and administrative expenses | 8 | 4 | 6 | 4 | 5 | |
| Operating Loss | −32 | −18 | −8 | −30 | −15 | |
| Employee Retention Tax Credit | 113,574 | — | — | 334,443 | — | |
| Grant income | 713,508 | 57,627 | — | 42,466 | — | |
| Interest expense | −625,283 | −4 | — | −18,688 | — | |
| Interest income | 136,233 | 361,632 | — | 89,673 | — | |
| Change in fair value of derivative liability | — | −313,772 | — | — | — | |
| Change in fair value of Kineta merger holdback shares | 2 | — | — | — | — | |
| Loss on Kineta employee separation payments assumed from merger | −185,019 | — | — | — | — | |
| Total Other Income (Expense) | 2 | −4 | — | 447,894 | — | |
| Net Loss | −30 | −22 | −8 | −29 | −15 | |
| Series A Preferred cash dividend | −8,356 | −2,089 | −8,000 | — | −8,000 | |
| Deemed dividend on warrant modifications | 0 | −965,177 | — | — | — | |
| Net Loss attributable to common stockholders | −30 | −23 | −9 | −29 | −15 | |
| Net Loss per share, basic | −0.63 | −1.21 | −0.32 | −2.47 | −9.27 | |
| Net Loss per share, diluted | −0.63 | −1.21 | — | −2.47 | — | |
| Weighted-average shares outstanding, basic | 48 | 19 | 26 | 12 | 2 | |
| Weighted-average shares outstanding, diluted | 48 | 19 | — | 12 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-06-30 | FY 2023 2023-12-31 | FY 2023 2023-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 13 | 5 | 4 | 2 | |
| Deposits, planned business acquisition (note 1) | — | 6 | — | — | — | |
| Stock Subscription Receivable | 500,000 | — | — | — | — | |
| Other current assets | 501,187 | 958,708 | — | 493,769 | — | |
| Total Current Assets | 5 | 20 | 6 | 4 | 3 | |
| Property and equipment, net | 300,639 | 123,366 | 674,000 | 182,170 | 709,000 | |
| Operating right-of-use assets | 384,530 | 199,160 | — | 20,820 | — | |
| Other noncurrent assets | 33,769 | 33,769 | — | — | — | |
| Goodwill | 11 | — | — | — | — | |
| In-process research and development | 11 | — | — | — | — | |
| Total Assets | 27 | 20 | 6 | 4 | 4 | |
| Accounts payable and accrued expenses | 6 | 5 | 2 | 3 | 3 | |
| Kineta severance promissory notes | 197,354 | — | — | — | — | |
| Lease liabilities, current | 199,041 | 159,844 | — | 20,820 | — | |
| Total Current Liabilities | 6 | 5 | 2 | 4 | 3 | |
| Lease liability, long term | 303,627 | 42,698 | — | — | — | |
| Deferred tax liability | 197,919 | — | — | — | — | |
| Total Liabilities | 6 | 5 | 2 | 6 | 3 | |
| Commitments and contingencies (note 14) | — | — | — | — | — | |
| Common stock, $0.001 par value, 200,000,000 and 75,000,000 shares authorized as of December 31, 2025 and 2024; 59,336,104 and 12,167,679 shares issued and outstanding as of December 31, 2025 and 2024. | 59,336 | 42,324 | 55,000 | 12,168 | 2,000 | |
| Additional paid-in capital | 162 | 125 | 153 | 87 | 141 | |
| Accumulated deficit | −141 | −111 | −160 | −88 | −151 | |
| Total Stockholders' Equity | 21 | 15 | 4 | −2 | 731,000 | |
| Total Liabilities and Stockholders' Equity (Deficit) | 27 | 20 | 6 | 4 | 4 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-06-30 | FY 2023 2023-12-31 | FY 2023 2023-06-30 |
|---|---|---|---|---|---|---|
| Net loss | −30 | −22 | — | — | — | |
| Stock compensation expense | 6 | 2 | — | 478,890 | — | |
| Depreciation and amortization | 71,265 | 116,710 | — | 177,377 | — | |
| Amortization of debt discount | 481,424 | 1 | — | 5,124 | — | |
| Loss on share issuance to Kineta separation payments | 185,019 | — | — | — | — | |
| Change in fair value of holdback shares | −2 | — | — | — | — | |
| Change in fair value of derivative liability | — | 313,772 | — | — | — | |
| Other current assets | 457,523 | −464,938 | — | −1,995 | — | |
| Other noncurrent assets | 154,998 | 106,613 | — | 151,173 | — | |
| Accounts payable and accrued expenses | −4 | 4 | −577,000 | 337,746 | −442,000 | |
| Net cash flows from operating activities | −28 | −15 | −7 | −12 | −12 | |
| Cash paid for Kineta acquisition, net of assumed cash | −1 | −6 | — | — | — | |
| Purchase of property and equipment | −76,083 | −57,906 | — | −79,224 | — | |
| Net cash flows from investing activities | −1 | −6 | −20,000 | −1 | −232,000 | |
| Series A Preferred dividend | −8,356 | — | −6,000 | — | −8,000 | |
| Repayment of assumed Kineta indeptedness | −434,000 | — | — | — | — | |
| Payments made on Kineta severance promissory notes | −394,709 | — | — | — | — | |
| Payments on equipment lease | −54,315 | — | — | — | — | |
| Proceeds from convertible notes payable | — | 29 | — | 3 | — | |
| Proceeds from bridge note | 3 | — | — | — | — | |
| Payment of bridge note | −2 | — | — | — | — | |
| Proceeds from issuance of common stock | 18 | 5 | — | — | — | |
| Proceeds from stock options exercised | — | 104,000 | — | — | — | |
| Proceeds from warrants exercised | 4 | 2 | — | — | — | |
| Payment of offering costs associated with issuance of common stock | −2 | −300,000 | — | — | −43,000 | |
| Payment of merger transaction costs | −500,000 | −4 | — | — | — | |
| Payment of debt issuance costs | — | −1 | — | — | — | |
| Payment of net liabilities assumed in reverse recapitalization | −550,000 | −796,912 | — | — | — | |
| Net cash flows from financing activities | 20 | 30 | 11 | 3 | 2 | |
| Net change in cash and cash equivalents | −9 | 9 | 3 | −11 | −10 | |
| Cash paid for interest | 59,364 | — | — | — | — | |
| Right-of-use asset recognized in exchange for operating lease obligations | 340,368 | 318,722 | — | — | — | |
| Right-of-use asset recognized in exchange for finance lease obligations | 172,453 | — | — | — | — | |
| Deferred offering costs not yet paid | 463,903 | — | — | — | — | |
| Consideration for Kineta acquisition issued in shares | 9 | — | — | — | — | |
| Net liabilities assumed in reverse recapitalization not yet paid | — | 550,000 | — | — | — | |
| Merger transaction costs not yet paid | — | 500,000 | — | — | — | |
| Derivative liability associated with make-whole premium | — | 2 | — | 137,000 | — | |
| Warrants issued recorded as a debt discount | 301,424 | 7 | — | — | — | |
| Shares issued for placement agent fees | — | 443,560 | — | — | — | |
| Contingent value rights associated with Kintara merger | — | 5 | — | — | — | |
| Warrants issued to financial advisor | — | 2 | — | — | — | |
| Shares issued for payment of bridge note | 2 | — | — | — | — | |
| Shares issued upon settlement of convertible notes | — | 28 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is TuHURA Biosciences, Inc./NV's CIK number?
TuHURA Biosciences, Inc./NV's SEC CIK number is 0001498382 (1498382). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find TuHURA Biosciences, Inc./NV's SEC filings?
All of TuHURA Biosciences, Inc./NV's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did TuHURA Biosciences, Inc./NV last report earnings?
TuHURA Biosciences, Inc./NV (HURA) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-227204). This is TuHURA Biosciences, Inc./NV's most recent earnings filing of record — not a forecast of its next earnings date.
What is TuHURA Biosciences, Inc./NV's most recent earnings 8-K?
TuHURA Biosciences, Inc./NV's latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001193125-26-227204. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View TuHURA Biosciences, Inc./NV's latest earnings 8-K →
Look up any company's CIK number →